Kazia says Sovargen doses first patient in Phase 1b/2a paxalisib trial for rare seizure disorders, triggers $2 million payment
Bitget2026/09/22 11:31- Sovargen dosed the first patient in a Phase 1b/2a trial of paxalisib for rare, treatment-resistant seizure disorders.
- No clinical results have been presented; data are expected later as enrollment and study follow-up continue.
- The start of dosing triggered a USD 2 million development milestone payment to Kazia under a 2024 licensing deal.
- The agreement shifts epilepsy development and commercialization to Sovargen in most markets, creating potential milestones up to USD 17 million.
- Kazia retains paxalisib’s main clinical focus in oncology while the partner tests the drug’s potential in neurological indications.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Citi optimistic about international oil companies: low-cost resource reserves being rebuilt may drive energy sector to reverse a decade-long valuation discount
With oil prices in the mid-$70s range, Citi believes that global international oil companies (IOCs) can deliver a free cash flow yield of 7% to 8%, and achieve a real growth rate of 4% to 5% over a period of time.
Honda Motor (HMC.US) Reports 65.7% Increase in Net Profit in the First Half, Plans to Expand Production Capacity in North America and Brazil
Honda Motor (HMC.US) released its financial results for the first half of fiscal year 2027 on November 10.
Crypto winter not over? Mining rig hosting provider Bitari cancels orders at the last minute, IPO plans put on hold
Bitcoin mining service provider Bitari has withdrawn its Nasdaq IPO plan. The company originally intended to issue 4.3 million shares at $7 per share to raise $30 million. Its annual revenue is approximately $11 million.
Crypto prices
More
